LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

Search

AbCellera Biologics Inc

Отворен

СекторЗдравеопазване

3.4 6.58

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.13

Максимум

3.59

Ключови измерители

By Trading Economics

Приходи

-22M

-57M

Продажби

-8.1M

9M

Марж на печалбата

-637.845

Служители

596

EBITDA

-1.4M

-40M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+119.44% upside

Дивиденти

By Dow Jones

Следващи печалби

7.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-698M

907M

Предишно отваряне

-3.18

Предишно затваряне

3.4

Настроения в новините

By Acuity

76%

24%

325 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

AbCellera Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.02.2026 г., 23:25 ч. UTC

Горещи акции

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25.02.2026 г., 23:15 ч. UTC

Печалби

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25.02.2026 г., 23:54 ч. UTC

Пазарно говорене

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25.02.2026 г., 23:47 ч. UTC

Печалби

Ferrovial 4Q Net EUR197M >FER.MC

25.02.2026 г., 23:45 ч. UTC

Печалби

Ferrovial 4Q Rev EUR2.72B >FER.MC

25.02.2026 г., 23:42 ч. UTC

Печалби

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Company's Business Operations Remain Normal >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY EPS CNY47.67 >TCOM

25.02.2026 г., 23:06 ч. UTC

Печалби

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25.02.2026 г., 23:01 ч. UTC

Печалби

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25.02.2026 г., 23:00 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

25.02.2026 г., 23:00 ч. UTC

Пазарно говорене
Печалби

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25.02.2026 г., 22:56 ч. UTC

Пазарно говорене
Печалби

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25.02.2026 г., 22:43 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25.02.2026 г., 22:40 ч. UTC

Пазарно говорене
Печалби

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25.02.2026 г., 22:40 ч. UTC

Печалби

Karoon Energy Says Search for New CFO Well Advanced

25.02.2026 г., 22:39 ч. UTC

Печалби

Karoon Energy Says CFO Ray Church to Leave Company

25.02.2026 г., 22:39 ч. UTC

Печалби

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25.02.2026 г., 22:38 ч. UTC

Печалби

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Сравнение с други в отрасъла

Ценова промяна

AbCellera Biologics Inc Прогноза

Ценова цел

By TipRanks

119.44% нагоре

12-месечна прогноза

Среден 7 USD  119.44%

Висок 7 USD

Нисък 7 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за AbCellera Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

1.99 / 2.635Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

325 / 351 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat